Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: A dichotomy of two ends of a spectrum

Netherlands Journal of Medicine

Volumn 69, Issue 9, 2011, Pages 367-371

  van Gulick, J J M ^a   Gevers, T J G ^a   van Keimpema, L ^a   Drenth, J P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADPKD; Diagnosis; Hepatic phenotype; Polycystic liver; Treatment

Indexed keywords

ANGIOPEPTIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; RAPAMYCIN; SOMATOSTATIN DERIVATIVE; TACROLIMUS; TOLVAPTAN;

CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); HUMAN; KIDNEY POLYCYSTIC DISEASE; LIVER CYST; LIVER POLYCYSTIC DISEASE; PATHOGENESIS; PHENOTYPE; REVIEW; TREATMENT INDICATION;

HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LIVER DISEASES; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT;

EID: 80054714430     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Ecder T, Fick-Brosnaha G, Schrier RW. Polycystic kidney disease. Diseases of the Kidney and Urinary Tract, 8th Ed., edited by Schrier RW, Philadelphia, Lippincott Williams & Wilkins, 2006:502-39.
2. Drenth JP, Martina JA, van de Kerkhof R, Bonifacino JS, Jansen JB. Polycystic liver disease is a disorder of cotranslational protein processing. Trends Mol Med. 2005;11(1):37-42.
3. Milutinovic J, Fialkow PJ, Rudd TG, Agodoa LY, Phillips LA, Bryant JI. Liver cysts in patients with autosomal dominant polycystic kidney disease. Am J Med. 1980;68:741-4.
4. Drenth JP, Chrispijn M, Bergmann C. Congenital fibrocystic liver diseases. Best Pract Res Clin Gastroenterol. 2010;24:573-84.
5. Davies F, Coles GA, Harper PS, Williams AJ, Evans C, Cochlin D. Polycystic kidney disease re-evaluated: a population-based study. Q J Med. 1991;79:477.
6. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD). The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003;64:1035-45.
7. Hateboer N, Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet. 1999;353:103-7.
8. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122-30.
9. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149-68.
10. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20:205-12.
11. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994;343:824-7.
12. Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008;3:1197-204.
13. Wuthrich RP, Serra AL, Kistler AD. Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney Blood Press Res. 2009;32:380-7.
14. Van Keimpema L, Nevens F, Vanselmbrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebocontrolled trial. Gastroenterology. 2009;137:1661-8.
15. Hogan M, Masyuk TV, Kim B, et al. A pilot study of long-acting octreotide (octreotide LAR depot) in the treatment of patients with severe polycystic liver disease. J Am Soc Nephrol. 2010;21(6):1052-61.
16. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363:820-9.
17. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010;363:830-40.
18. Wang X, Gattone V, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846-51.
19. Torres VE, Meijer E, Bae KT, et al. Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study. Am J Kidney Dis. 2011:692-9.
20. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the consortium for radiologic imaging studies of polycystic kidney disease cohort. Clin J Am Soc Nephrol. 2006;1:64-9.
21. Chapman AB. Cystic disease in women: clinical characteristics and medical management. Adv Ren Replace Ther. 2003;10:24-30.
22. Gabow PA, Johnson AM, Kaehny WD, et al. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. Hepatology. 1990;11:1033-7.
23. Nicolau C, Torra R, Badenas C, et al. Autosomal dominant polycystic kidney disease types 1 and 2: assessment of US sensitivity for diagnosis. Radiology. 1999;213:273-6.
24. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology. 1997;26:1282-6.
25. Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine3',5'-cyclic monophosphate. Gastroenterology. 2007;132:1104-16.
26. Torres VE. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1999;34:xlv-xlviii.
27. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int. 2008;28(2):264-70.
28. Alvaro D, Mancino MG, Onori P, et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol. 2006;12(22):3537-45.
29. Van Keimpema L, de Koning DB, Strijk SP, et al. Aspiration-sclerotherapy results in effective control of liver volume in patients with liver cysts. Dig Dis Sci. 2008;53:2251-7.
30. Yamada N, Shinzawa H, Ukai K, et al. Treatment of symptomatic hepatic cysts by percutaneous instillation of minocycline hydrochloride. Dig Dis Sci. 1994;39:2503-9.
31. Moorthy K, Mihssin N, Houghton PW. The management of simple hepatic cysts: sclerotherapy or laparoscopic fenestration. Ann R Coll Surg Engl. 2001;83:409-14.
32. Okano A, Hajiro K, Takakuwa H, et al. Alcohol sclerotherapy of hepatic cysts: its effect in relation to ethanol concentration. Hepatol Res. 2000;17:179-84.
33. Van Keimpema L, Ruurda JP, Ernst MF, et al. Laparoscopic fenestration of liver cysts in polycystic liver disease results in a median volume reduction of 12.5%. J Gastrointest Surg. 2008;12:477-82.
34. Schnelldorfer T. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg. 2009;250:112-8.
35. Van Keimpema L, Hockerstedt K. Treatment of polycystic liver disease. Br J Surg. 2009;96(12):1379-80.
36. Kirchner GI, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl. 2006;12:1268-77.
37. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9:1231-43.
38. Caroli A, Antiga L, Cafaro M, et al. Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol. 2010;5(5):783-9.
39. Van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in polycystic liver disease. Gut. 2008;57:1338-9.
40. Van Keimpema L, Drenth JP. Effect of octreotide on polycystic liver volume. Liver Int. 2010;30:633-4.
41. Qian Q, Du H, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J Am Soc Nephrol. 2008;19:631-8.
42. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med. 2009;60:321-37.
43. Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol. 2001;21(2):107-23.
44. Onori P, Franchitto A, Mancinelli R, et al. Polycystic liver diseases. Dig Liver Dis. 2010;42:261-71.